INSM Stock Recent News

The headline numbers for Insmed (INSM) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Insmed (INSM) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.22. This compares to loss of $1.17 per share a year ago.

Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

BRIDGEWATER, N.J. , May 7, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that management will present in a fireside chat at the BofA Securities Health Care Conference 2024 in Las Vegas, NV, on Tuesday, May 14, 2024 at 2:20 p.m.

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) came out with a quarterly loss of $1.28 per share versus the Zacks Consensus Estimate of a loss of $1.13. This compares to loss of $1.20 per share a year ago.

Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Insmed (INSM) came out with a quarterly loss of $1.10 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to loss of $1.09 per share a year ago.

Insmed is looking to broaden the use of its only approved therapy, Arikayce. The company had a record $72 million in revenue in the second quarter.

Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.